EP3583122A4 - Monoklonale antikörper und cocktails zur behandlung von ebola-infektionen - Google Patents

Monoklonale antikörper und cocktails zur behandlung von ebola-infektionen Download PDF

Info

Publication number
EP3583122A4
EP3583122A4 EP18754083.6A EP18754083A EP3583122A4 EP 3583122 A4 EP3583122 A4 EP 3583122A4 EP 18754083 A EP18754083 A EP 18754083A EP 3583122 A4 EP3583122 A4 EP 3583122A4
Authority
EP
European Patent Office
Prior art keywords
cocktails
treatment
monoclonal antibodies
ebola infections
ebola
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18754083.6A
Other languages
English (en)
French (fr)
Other versions
EP3583122A1 (de
Inventor
Zachary A. BORNHOLDT
Larry Zeitlin
Kartik Chandran
Anna WEC
Laura Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Adimab LLC
Mapp Biopharmaceutical Inc
Original Assignee
Albert Einstein College of Medicine
Adimab LLC
Mapp Biopharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine, Adimab LLC, Mapp Biopharmaceutical Inc filed Critical Albert Einstein College of Medicine
Priority claimed from PCT/US2018/018559 external-priority patent/WO2018152452A1/en
Publication of EP3583122A1 publication Critical patent/EP3583122A1/de
Publication of EP3583122A4 publication Critical patent/EP3583122A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP18754083.6A 2017-02-17 2018-02-17 Monoklonale antikörper und cocktails zur behandlung von ebola-infektionen Pending EP3583122A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762460200P 2017-02-17 2017-02-17
PCT/US2018/018559 WO2018152452A1 (en) 2017-02-17 2018-02-17 Monoclonal antibodies and cocktails for treatment of ebola infections

Publications (2)

Publication Number Publication Date
EP3583122A1 EP3583122A1 (de) 2019-12-25
EP3583122A4 true EP3583122A4 (de) 2020-11-11

Family

ID=68578582

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18754083.6A Pending EP3583122A4 (de) 2017-02-17 2018-02-17 Monoklonale antikörper und cocktails zur behandlung von ebola-infektionen

Country Status (1)

Country Link
EP (1) EP3583122A4 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANNA Z. WEC ET AL: "Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses", CELL, vol. 169, no. 5, 1 May 2017 (2017-05-01), AMSTERDAM, NL, pages 878 - 890.e15, XP055510476, ISSN: 0092-8674, DOI: 10.1016/j.cell.2017.04.037 *
ANNA Z. WEC ET AL: "Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection", CELL HOST & MICROBE, vol. 25, no. 1, 1 January 2019 (2019-01-01), NL, pages 39 - 48.e5, XP055736663, ISSN: 1931-3128, DOI: 10.1016/j.chom.2018.12.004 *
See also references of WO2018152452A1 *
Z. A. BORNHOLDT ET AL: "Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak (Author Manuscript)", SCIENCE, vol. 351, no. 6277, 18 February 2016 (2016-02-18), pages 1078 - 1083, XP055549012, ISSN: 0036-8075, DOI: 10.1126/science.aad5788 *
Z. A. BORNHOLDT ET AL: "Supplemental material Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak", SCIENCE, 18 February 2016 (2016-02-18), pages 1 - 39, XP055736566, Retrieved from the Internet <URL:https://science.sciencemag.org/content/sci/suppl/2016/02/17/science.aad5788.DC1/aad5788-Bornholdt-SM.pdf> [retrieved on 20201005], DOI: 10.1126/science.aad5788 *

Also Published As

Publication number Publication date
EP3583122A1 (de) 2019-12-25

Similar Documents

Publication Publication Date Title
IL276164A (en) Antibodies against TMPRSS2 and antigen-binding fragments
EP3538152A4 (de) Anti-ox40-antikörper, anti-gitr-antikörper und verfahren zur verwendung davon
TWI799432B (zh) 抗ctla-4抗體及其用途
EP3244926B8 (de) Behandlung von krebs mit monoklonalen-anti-lap-antikörpern
EP3797123A4 (de) Anti-ox40-antikörper und verfahren zur verwendung
EP3399989A4 (de) Anti-lag3-antikörper und antigenbindende fragmente
EP3426686A4 (de) Humanisierte anti-pacap-antikörper und verwendungen davon
EP3414573A4 (de) Neuartige anti-lam- und anti-pim6/lam-monoklonale antikörper zur diagnose und behandlung von mycobacterium-tuberculosis-infektionen
EP3307322A4 (de) Humanisierte anti-cd40-antikörper und verwendungen dafür
EP3176182A4 (de) Monoklonaler anti-pd-1-antikörper und herstellungsverfahren dafür
EP3472200A4 (de) Anti-myostatin-antikörper und verfahren zur verwendung
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
EP3280440A4 (de) Humanisierte anti-c1s-antikörper und verfahren zur verwendung davon
EP3675906A4 (de) Anti-tm4sf1-antikörper und verfahren zu deren verwendung
EP3846850A4 (de) Humanisierte anti-c5-antikörper und verwendungen davon
EP3291837A4 (de) Monoklonale antikörpercocktails zur behandlung von ebola-infektionen
EP3733705A4 (de) Monoklonale antikörper und verfahren zu ihrer verwendung
ZA201805051B (en) Egfl6 specific monoclonal antibodies and methods of their use
EP3893931A4 (de) Verfahren zur verwendung von anti-trem2-antikörpern
EP3183002A4 (de) Monoklonale antikörper zur behandlung mikrobieller infektionen
EP3529274A4 (de) Monoklonaler antikörper und verfahren zur verwendung zur behandlung von lupus
EP4061847A4 (de) Monoklonaler anti-b7-h3-antikörper und verfahren zur verwendung davon
EP3404042A4 (de) Monoklonaler antikörper fnab8 und anwendung davon
IL273538A (en) Anti-TRKB Monoclonal Antibodies and Methods of Use
EP3906261A4 (de) Humanisierte und affinitätsgereifte anti-ceacam1-antikörper

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHANDRAN, KARTIK

Inventor name: BORNHOLDT, ZACHARY, A.

Inventor name: WALKER, LAURA

Inventor name: WEC, ANNA

Inventor name: ZEITLIN, LARRY

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201014

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/10 20060101AFI20201008BHEP

Ipc: A61K 39/395 20060101ALI20201008BHEP

Ipc: A61P 31/14 20060101ALI20201008BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MAPP BIOPHARMACEUTICAL, INC.

Owner name: ADIMAB, LLC

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE